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JAK2 constitutive activation/overexpression is common in classicalHodgkin lymphoma, and several cytokines stimulate Hodgkin lym-phoma cells by recognizing JAK1-/JAK2-bound receptors. JAK block-
ade may thus be therapeutically beneficial in Hodgkin lymphoma. In this
phase II study we assessed the safety and efficacy of ruxolitinib, an oral
JAK1/2 inhibitor, in patients with relapsed/refractory Hodgkin lym-
phoma. The primary objective was overall response rate according to the
International Harmonization Project 2007 criteria. Thirty-three patients
with advanced disease (median number of prior lines of treatment: 5;
refractory: 82%) were included; nine (27.3%) received at least six cycles
of ruxolitinib and six (18.2%) received more than six cycles. The overall
response rate after six cycles was 9.4% (3/32 patients). All three respon-
ders had partial responses; another 11 patients had transient stable dis-
ease. Best overall response rate was 18.8% (6/32 patients). Rapid allevia-
tion of B-symptoms was common. The median duration of response was
7.7 months, median progression-free survival 3.5 months (95% CI: 1.9-
4.6), and the median overall survival 27.1 months (95% CI: 14.4-27.1).
Forty adverse events were reported in 14/33 patients (42.4%). One event
led to treatment discontinuation, while 87.5% of patients recovered
without sequelae. Twenty-five adverse events were grade 3 or higher.
These events were mostly anemia (n=11), all considered related to ruxoli-
tinib. Other main causes of grade 3 or higher adverse events included
lymphopenia and infections. Of note, no cases of grade 4 neutropenia or
thrombocytopenia were observed. Ruxolitinib shows signs of activity,
albeit short-lived, beyond a simple anti-inflammatory effect. Its limited
toxicity suggests that it has the potential to  be combined with other ther-
apeutic modalities. ClinicalTrials.gov: NCT01877005
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ABSTRACT
Preliminary results were presented at the 58th
Annual Meeting of the American Society of
Hematology, held on December 3 – 6, 2016,
in San Diego, USA.
Introduction
Hodgkin lymphoma (HL) is regarded as a curable malig-
nancy in most cases, yet treatment failure still occurs in
about 10% of patients with early-stage disease.1 In
advanced-stage disease, up to 10% of cases do not reach
complete remission and are thus considered to have pri-
mary refractory HL,2 while 20-30% of primary responders
eventually relapse following first-line treatment.3
For most patients with relapsed or refractory HL (R/R
HL), the standard of care consists of high-dose salvage
chemotherapy followed by autologous stem-cell transplan-
tation (SCT). For patients who develop R/R HL within 1
year of autologous SCT, the prognosis proves extremely
poor, since they have a median survival of 1.2 years.4 For
patients in whom all classical approaches have failed, new
strategies, including checkpoint inhibitors targeting PD-1
and antibody-drug conjugates targeting CD30, have
become part of the therapeutic armamentarium against
R/R HL.5-8 However, patients with multiple relapses or
those who develop refractory disease remain in medical
need, especially those in whom treatment with brentux-
imab-vedotin (BV) and PD-1 blockers fails.
Classical HL is characterized by the presence of
Hodgkin and Reed-Sternberg (HRS) cells and their vari-
ants.9 HRS cells were demonstrated to shape their envi-
ronment by secreting immunosuppressive cytokines and
chemokines.10 With this in mind, the Janus kinase (JAK) –
signal transducer and activator of transcription (STAT)
pathway appears to be a relevant cytokine-induced signal
transduction pathway that has been shown to transfer sig-
nals directly from cell surface cytokine receptors to the cell
nucleus. Given that enhanced JAK-mediated signaling has
been demonstrated in a significant number of HL
patients,11 this signaling pathway has become a focus for
developing novel therapeutic agents for the disease. Van
Roosbroeck et al. reported the translocation of JAK2 in
several cases of HL,12 and JAK inhibition was shown to
decrease the proliferation of cell lines. Although such
translocations are relatively rare, 9p24.1 genomic amplifi-
cation including the JAK2 locus appears common in HL,
along with increased protein expression and activity,
resulting in the constitutive activation of STAT6, an essen-
tial messenger of tumor cell growth.13-15 In corollary, JAK
1/2 inhibition may be suitable to target the constitutive
activation caused by either JAK2 translocation or JAK2
amplification and to modify the reactive microenviron-
ment which contributes to HL growth via aberrant
cytokine production.16
Ruxolitinib is the first potent, selective, and oral inhibitor
of JAK1/2 being developed for clinical use.17 Its major
effects include inhibition of proliferation, induction of
apoptosis, and reduction in cytokine plasma levels, all
mediated by the drug's ability to inhibit JAK-induced phos-
phorylation of STAT.18 Used in the treatment of myelofi-
brosis, ruxolitinib had durable efficacy in reducing
splenomegaly and alleviating constitutional symptoms, the
patients gained weight and their general physical condition
improved.19 The dose-limiting toxicity was thrombocy-
topenia, which was fairly well managed by dose reduc-
tions or brief interruptions of treatment. In the present
phase II study, we sought to investigate the safety and effi-
cacy of ruxolitinib in patients with R/R HL. Exploratory
biomarker analyses pertaining to plasma cytokine profiles
and aberrations of JAK2 were also carried out. 
Methods
Patients’ eligibility
Patients aged 18 years or older with a diagnosis of R/R HL for
whom no treatment with proven efficacy was available were eli-
gible to enter the trial after having receiving at least one prior
therapy provided that they had measurable nodal disease at
baseline (≥1 cm in the longest transverse diameter, clearly meas-
urable in at least two perpendicular dimensions) on computed
tomography or magnetic resonance imaging, as well as an
Eastern Cooperative Oncology Group performance score of ≤3.
Additional inclusion criteria were an absolute neutrophil count
≥1.0 x 109/L, platelet count ≥75 x 109/L, serum creatinine ≤1.5 x
upper limit of normal, serum bilirubin ≤1.5 x upper limit of nor-
mal, and ALT and AST levels ≤2.5 or ≤5.0 x upper limit of nor-
mal in the event the transaminase increase was due to HL-relat-
ed liver disease. Pregnant or lactating patients were not allowed
to enter the trial, and men and women of childbearing potential
had to agree to employ an adequate contraceptive method dur-
ing the study treatment. Patients were permitted to have
received an undefined number of prior lines of therapy, and a
previous allogeneic SCT was likewise allowed provided that
patients had not received any immunosuppressive therapy with-
in the 90 days prior to starting the screening procedures. Patients
were required to have a life expectancy of ≥3 months. 
Study design and treatment
This multicenter, open-label, phase II study (HIJAK,
NCT01877005) was conducted at ten LYSA centers in France and
Belgium, with patients recruited from July 2013 through
December 2014. Its primary efficacy endpoint was overall
response rate (ORR), defined as the proportion of patients with a
complete response or partial response at 6 months of treatment by
investigator assessment based on the revised 2007 International
Harmonization Project response criteria for malignant lym-
phoma.20 Secondary objectives included relief of B symptoms, best
ORR (occurring at any time during study), duration of response,
progression-free survival, overall survival, as well as the incidence
and severity of adverse events. 
The study was carried out in line with the ethical principles of
the Helsinki Declaration and in compliance with the International
Conference on Harmonization Guideline for Good Clinical
Practice. The protocol was approved by the institutional review
board of each study site and written informed consent was
obtained from all patients.
The starting dose of ruxolitinib was 20 mg given twice daily dur-
ing six 28-day cycles for the induction period if the platelet count
was >200 x 109/L. The ruxolitinib dose was decreased to 15 mg
twice daily in patients with platelet counts between 75 x 109/L and
200 x 109/L. Patients who achieved at least stable disease at the end
of cycle 6 and who had, in the investigator's opinion, a clinical ben-
efit were eligible to continue ruxolitinib (15 mg or 20 mg), which
was defined as “maintenance” therapy. Treatment could be contin-
ued for up to 2 years or until progressive disease, intolerability, or
as long as the investigator thought that there was clinical benefit.
Administration of the study drug could be stopped for any grade
≥3 non-hematologic toxicity, with the exception of deep venous
thrombosis and alopecia. Following event resolution to grade ≤1,
ruxolitinib could be resumed, with a 5 mg dose reduction and a
maximum delay of 4 weeks. Mandatory dose decreases or inter-
ruptions for hematologic toxicity as well as the rules for perma-
nent discontinuation are detailed in the Online Supplementary
Appendix. Growth factors were allowed as per American Society of
Clinical Oncology guidelines and infectious prophylaxis as per the
guidelines of Heine et al.21
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Study assessments
Baseline assessments comprised documentation of disease-
related symptoms, physical examination, laboratory tests, and
imaging studies of the neck, chest, abdomen, and pelvis, using
computed tomography or magnetic resonance imaging. Biopsy
prior to inclusion was recommended, but not mandatory. Tumors
were measured at baseline, at the end of every two cycles of rux-
olitinib, and following the six-cycle induction, as well as during
maintenance therapy. Given the exploratory nature of the study,
there was no centralized review of computed tomography
response. However, positron emission tomographic images of the
responders were all centrally reviewed by a nuclear physician
(ASC) to confirm partial or complete metabolic response based on
the Deauville five-point scale. The evaluable study population for
efficacy was restricted to patients who had received at least 28
days of the study drug. 
Safety was monitored for up to 1 month after treatment.
Adverse events were summarized by means of the Medical
Dictionary for Regulatory Activities, and graded using the
National Cancer Institute’s Common Terminology Criteria for
Adverse Events (NCI-CTCAE), version 3.0. Laboratory abnormal-
ities were assessed according to NCI-CTCAE version 4.0. Only
grade 3 or 4 toxicities and grade 2 infections were to be reported.
All patients were included in the toxicity analysis.
Exploratory biomarker analysis
Blood samples (5 mL) were taken at baseline prior to drug
administration and on day 1 of cycle 2 for the measurement of
27 cytokines related to the immune system using bead-based
immunoassays. JAK2 gains, amplifications, and gene rearrange-
ments were also investigated using fluorescent in situ hybridiza-
tion with two tri-color sets of probes associating JAK2/9p24
break-apart probes with a control centromeric probe
(CEP9/9q21): the already prepared probes from Empire
genomics on the one hand, and the association of the JAK2 B/A
probe from Kreatech with the CEP9 probe from Vysis on the
other hand. The CD274/PDL1 and PDCD1LG2/PDL2 loci at
9p24 were studied with home-made prepared bacterial artificial
chromosome probes purchased from the Chori BACPAC
Resources Center (Oakland, CA, USA). Extraction, labeling and
hybridization were performed on paraffin-embedded tissue, as
previously reported.22
Statistical methods
The sample size for this phase II study was calculated using
an exact single-stage phase II design.23 A two-stage design with
interim analysis for activity or toxicity was not planned given
the very advanced stage of the patients, the relative paucity of
alternative options, and the potential toxicity of ruxolitinib that
was expected to be in the low range, based on myelofibrosis
data. The treatment was considered ineffective if the ORR was
≤15%, and effective if the ORR was ≥35%. Under the assump-
tion of an alpha first-order risk error set at 5% and beta at 20%
with a one-sided test, it was deemed necessary to include a
total of 28 evaluable patients with a cut-off number of eight. If
at least eight patients had a response, the hypothesis of an ORR
≤15% was rejected with both a target error rate and an actual
error rate of 0.05. If seven or fewer patients had a response, the
hypothesis of an ORR ≥35% was rejected with a target error
rate of 0.2 and an actual error rate of 0.187. The ORR estimate
and its 90% confidence intervals (CI) were calculated for all
patients who completed at least one cycle of the study drug. 
The Kaplan-Meier method was employed to estimate the
median value and its 95% CI for time to response, duration of
response, progression-free survival and overall survival. The
safety analysis comprised all patients who received at least one
dose of the study drug. All statistical analyses were performed
using SAS software, version 9.2. P-values <0.05 were consid-
ered statistically significant. All available data were included in
data listings and tabulations, with no imputations of values for
missing data. An interim analysis was neither planned nor per-
formed. 
Results
Patients’ disposition and characteristics
The patients’ characteristics are listed in Table 1. From
July 2013 to December 2014, a total of 33 patients with
R/R HL were recruited. Their median age was 37 years
(range, 19-80). Most of the patients had advanced HL
(stage III/IV) and had been heavily pretreated, with a
median number of five prior regimens including autolo-
gous SCT (54%), allogeneic SCT(15%), and BV (82%).
Of the 33 patients recruited, 27 (82%) had refractory HL
and 22 had biopsy-confirmed relapse of HL. Among the
six patients displaying a response, a biopsy was per-
formed in five of them at relapse [8 days, 12 days, 6
weeks (n=2) and 14 months prior to inclusion in the
study].
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Table 1. Patient’s demographics and characteristics.
Patients’ demographics and characteristics                 All patients (n=33)
Gender, n (%)
Male                                                                                                     21 (63.6%)
Female                                                                                                12 (36.4%)
Age in years, median (range)                                                      37.0 (19.0-80.0)
ECOG score
0                                                                                                            11 (33.3%)
1                                                                                                            15 (45.5%)
2                                                                                                             5 (15.2%)
3                                                                                                              2 (6.1%)
Ann Arbor stage
I                                                                                                               1 (3.0%)
II                                                                                                            7 (21.2%)
III                                                                                                            3 (9.1%)
IV                                                                                                          22 (66.7%)
B symptoms
Yes                                                                                                       16 (48.5%)
No                                                                                                         17 (51.5%)
Extranodal involvement
Bone                                                                                                    13 (39.4%)
Liver                                                                                                      6 (18.2%)
Lung                                                                                                     12 (36.4%)
Soft tissues                                                                                         4 (12.1%)
Time since initial diagnosis in months, median (range)    55.4 (8.7 – 216.1)
Prior therapies
Prior lines, median (range)                                                           5 (1 – 16)
Chemotherapy                                                                                   33 (100%)
Radiotherapy                                                                                     18 (54.5%)
Brentuximab vedotin                                                                        27 (82%)
Autologous SCT                                                                                 18 (54.5%)
Allogeneic SCT                                                                                   5 (15.2%)
Interval since last treatment in months, median (range)   6 (1.1 – 75.0)
Disease status at inclusion
Relapse                                                                                                        6
Refractory                                                                                          27 (81.8%)
SCT: stem cell transplantation; ECOG: Eastern Cooperative Oncology Group.
Patients’ exposure to the study drug
The median number of ruxolitinib cycles administered
was four (range, 1 to 12) (Table 2). Nine patients received
all six of the planned cycles of ruxolitinib and six of these
patients continued on maintenance therapy with the JAK
inhibitor. The remainder discontinued ruxolitinib therapy,
most because of progressive disease and in one case due to
adverse events. 
Responses and outcomes
The patients’ disposition through the study is illustrated
in Figure 1. Among the 33 HL patients included in the trial,
one patient did not complete the first cycle of treatment
because of progressive disease and was not, therefore,
included in the efficacy analysis. At the end of the ruxoli-
tinib induction period (6 months) three of 32 patients had
a response, for an ORR of 9.4% (90% CI: 2.6-22.5%); the
response in all three was partial. At some point during
induction six of the 32 patients had a response, which
was, in all six cases a partial response, for a best ORR of
18.8% (95% CI: 7.2-36.4%). A detailed analysis of the
responders’ characteristics is provided in Table 3. Figures 2
and 3 illustrate metabolic evolution in two patients.
Interestingly, UPN 611001, who had achieved a partial
response after six cycles of treatment, eventually entered
complete remission during the follow-up, beyond the six
cycles. Achievement of complete metabolic response was
confirmed by central review. At the time of writing, two
patients (UPN 611001 and 881001) are still taking ruxoli-
tinib. Figure 4 illustrates changes in target tumor measure-
ments in individual patients. The best reduction, if any, at
any time throughout treatment is shown.
In addition, during the 6-month induction, transient sta-
ble disease was recorded in 11 patients, albeit of limited
duration. Overall, the disease control rate (including stable
disease with complete and partial responses) was 53.1%
(17/32 patients) (95% CI: 34.7-70.9%) with a median
duration of 1.9 months.
The alleviating effect on systemic symptoms, such as
pruritus, fever, and sweating, was noteworthy, starting
within the first month of drug administration and com-
monly lasting. The impact was most remarkable on the
Ruxolitinib in advanced relapsed/refractory HL
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Table 2. Treatment exposure and modifications.
Treatment exposure and modifications                         All patients (n=33)
Cycles given, number, median (range)                                           4 (1-22)
Received full induction (6 cycles), %                                          9 (27.3%)
Received maintenance (> 6 cycles), %                                       6 (18.2%)
Percentage of planned dosea
<75%                                                                                                     3 (9.1%)
75%-90%                                                                                              4 (12.1%)
90%-110%                                                                                           25 (75.8%)
110%-125%                                                                                           1 (3.0%)
Dose modification
Yes                                                                                                       20 (60.6%)
Type of modificationb                                                                                
Dose reduction                                                                              2 (10.0%)
Dose interruption                                                                        18 (90.0%)
Dose increase                                                                                3 (15.0%)
Number of days of interruption if any,                                       4 (1 – 28)
median (range)                                                                                          
aDefined as follows: (total number of tablets taken/total expected number of tablets)
*100, taking into account protocol-defined dose reduction. bThe total sum of the per-
centages for the type and the reasons of modification may be greater than 100.0% as
a patient may have had several types of modification and reasons for treatment mod-
ification.
Table 3. Characteristics of responders (best response achieved during the 6-month ruxolitinib induction).
UPN Prior treatment                                                                           Extranodal involvement     Response (Cheson 2007)20
                               N                                                              Type                                                                                                                
611001                          9                            ABVD, BEACOPP, MINE, IGEV, GVD, CAELYX, GVD, RT, BV                             Liver                                            PR*,1
211004                          8                               ABVD, RT, IVA, transplantation, MINE, GVD, BV, ASHAP                              Breast                                             PR
601001                          5                                       BEACOPP, DHAP, IGEV, transplantation-RT, BV                             Liver, bone, lung                                    PR
601004                          5                                                           ABVD, DHAP, RT, RT, BV                                                            None                                              PR
641001                          1                                                                           ABVD2                                                                            None                                              PR
881001                          5                                          ABVD, transplantation, MINE, BV, GEMOX                                           Lung                                              PR1
*Patient eventually achieved a complete response during maintenance therapy. 1Patients still under treatment with ruxolitinib at the time of writing; 2Patient with morbid obesity
not eligible for standard approaches with chemo/immunotherapy. UPN:unique patient number; RT: radiotherapy; BV: brentuximab vedotin; PR: partial response.
Figure 1. Patients’ disposition. *N months on maintenance therapy: 4, 6, 6, 21,
16, 22; PD: progressive disease.
control of pruritus, which affected 35.5% of patients prior
to initiating therapy but only 6.6% after the first cycle of
ruxolitinib. Sweating, which was present in 32.2% of the
patients at inclusion, was reduced, with 20% still having
this symptom after one cycle of treatment. Fever was
abolished in 3/4 patients with this symptom at inclusion.
The median follow-up was 17.5 months. As illustrated
in Figure 5, the median progression-free survival was 3.5
months (95% CI: 1.9-4.6). The median duration of
response was 7.7 months (95% CI: 1.8-NA) for the six
patients who eventually a achieved response (data not
shown). Overall, 30 patients had progressive disease, with
97% at the initial site and/or 60% at new sites. Following
ruxolitinib discontinuation, 25 (83.3%) patients were
given further treatments, consisting of chemotherapy in
19, and immunotherapy in nine, the latter comprising rit-
uximab in four, BV in three, and nivolumab in two.
Transplantation was eventually carried out in five
patients, and was allogeneic in four cases and autologous
in the remaining one. Among the 25 patients prescribed
further therapy, the observed complete and partial
response rates were 10% and 15%, respectively. Overall,
12 patients died on account of lymphoma progression
(83.3%), toxicity of other treatments (8.3%), or other rea-
sons (8.3%). The median overall survival was 27.1 months
(95% CI: 14.4-27.1).
Safety
All patients enrolled in the study received at least one
dose of study medication and were, therefore, included in
the safety analysis. Overall, 40 adverse events were
observed in 14/33 patients (42.4%). In six patients, the
adverse events were related to the ruxolitinib therapy. In
eight of them, the events were of grade ≥3 (Table 4A).
Among the 40 adverse events recorded, 30 (75%) occurred
during induction and 18 (45%) were related to ruxolitinib.
No drug-related deaths were recorded. One adverse event
resulted in permanent drug discontinuation, while 87.5%
of the adverse events resolved without sequelae. The
characteristics and grade of the adverse events, listed by
system organ class and preferred terms, are displayed in
Table 4B. Twenty-five (62.5%) were of grade ≥3. These
were mostly anemia (n=11), all considered related to rux-
olitinib. Other main causes of grade ≥3 adverse events
included lymphopenia (n=4), infections (n=3) and miscel-
laneous causes. Of note, no cases of grade 4 neutropenia
or thrombocytopenia were observed. 
Eight serious adverse events were reported in four
patients, during induction (n=5), maintenance (n=1) or
after the end of treatment (n=2). These serious adverse
events consisted of infection in three patients (device-
related sepsis, gastroenteritis, and lung infection). The
other serious adverse events were anemia, diarrhea, sub-
dural hematoma, bone pain, and pulmonary embolism.
Two serious adverse events (anemia, lung infection) were
deemed drug-related and six were considered grade ≥3:
infection (n=3), anemia, subdural hematoma, and pul-
monary embolism. Of the eight serious adverse events, six
resolved without sequelae, while the device-related sepsis
and pulmonary embolism, observed in the same patient,
persisted until the patient died due to progressive disease
and were thus not considered as the cause of death.
Among the 33 patients, one second primary malignancy
was observed (adenocarcinoma of the colon in an 80-year
old male patient).
Biomarker analysis
Using bead-based immunoassays, plasma levels of 27
cytokines related to the immune system were measured at
E. Van Den Neste et al.
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Figure 2. Response after ruxolitinib. Illustrative patient (UPN 601004). (A)
Positron emission tomography (PET)-computer tomography (CT) frontal view. (B)
PET-CT sagittal view. Partial response with allievation of B symptoms and blood
inflammation was achieved 2 months after starting ruxolitinib. At month 6, the
patient had slowly progressive disease but refused to stop ruxolitinib. CRP: C-
reactive protein.
Figure 3. Response after ruxolitinib. Illustrative patient (UPN 601001).
Comparison of frontal positron emission tomography (PET)-scan prior to inclu-
sion and after 2 months of ruxolitinib. There was a rapid improvement of con-
stitutional symptoms after a few days on ruxolitinib. PET after 2 months showed
metabolic partial response with a total volume reduction of tumor lung lesions
of 64%.
A
B
baseline and after the first cycle of treatment. At baseline,
there was no difference in cytokine levels between
responders and non-responders. In responders, the only
cytokine that decreased significantly was CX-CL10
(P=0.01). In patients presenting with pruritus (n=11), the
levels of platelet-derived growth factor-BB (PDGF-BB)
(Online Supplementary Appendix), interleukin (IL)-5, IL-10,
IL-12, IL-13, IL-17, eotaxin, fibroblast growth factor basic
(FGF basic), macrophage inflammatory protein 1b
(MIP1b), regulated on activation, normal T-cell expressed
and secreted (RANTES), and vascular endothelial growth
factor (VEGF) were significantly increased. In the latter
patients, ruxolitinib treatment significantly decreased the
levels of PDGF-BB, IL-10, IL-12, IL-13, IL-17, FGF basic
and VEGF. Among the patients who could be analyzed for
JAK2 amplification in HRS cells (n=12), polysomy (sug-
gesting hyperdiploidy) was detected in all of them, and
specific JAK2 amplification in only one. This latter patient
achieved a partial response as determined by computed
tomography criteria and also a positron emission tomog-
raphy-determined response lasting 4 months. It is note-
worthy that the PDL1 and PDL2 loci (which are in the
vicinity of the JAK2 locus at 9p24), analyzed by fluores-
cent in situ hybridization with bacterial artificial chromo-
some probes, showed the same pattern of gains as for the
JAK2 locus.
Discussion 
JAK/STAT activation, driven by an aberrant network of
cytokines and chemokines in the HL microenvironment,
is critical for the proliferation and survival of neoplastic
HRS cells.24,25 The JAK/STAT pathway also plays a role in
immune evasion by HL cells via the secretion of
chemokines leading to Th2 homing or via the regulation
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Figure 4. Waterfall plot demonstrating percent
change from baseline in target tumor dimensions
(best response, n=27). Of note, among the 32
patients evaluable for disease response, five had no
end-of-treatment SPD measurements by computer
tomography (CT) scan as planned by protocol
because there were obvious signs of disease progres-
sion. *Persisting positive positron emission tomogra-
phy scan, considered as partial response.
Figure 5. Kaplan-Meier estimate of progression-free
survival in 32 evaluable patients with Hodgkin lym-
phoma receiving ruxolitinib. 
of PD-L1/L2 expression, which confers an immune privi-
lege to HRS cells. Chromosome 9p24.1/PD-L1/PD-L2
alterations increase the abundance of the PD-1 ligands,
PD-L1 and PD-L2, and their further induction through
JAK/STAT signaling.26-28 This complex crosstalk between
malignant HRS cells and the reactive microenvironment
could be targeted to overcome chemoresistance. Based on
this rationale, we explored JAK 1/2 inhibition in a phase
II study of fixed dose ruxolitinib in patients with
advanced HL patients before the onset of the era of PD-1
blockers. With an ORR of 9.4% at the end of the 6-month
induction period, this study did not reach its primary effi-
cacy goal. Nevertheless, when including transient
responses seen before the 6-month evaluation, the ORR
was 18.8% in some heavily pretreated patients, most of
whom were refractory and had failed treatment with BV.
These responses were sometimes durable (median=7.7
months). Some other patients had disease control, but
with uncertain clinical benefit. A notable finding to be
highlighted was the relief of B symptoms and pruritus,
which was quick and long-lasting, resulting in a number
of patients being reluctant to discontinue the compound,
despite progressive disease. The latter effect should not
be interpreted as a proven surrogate of anti-lymphoma
activity.
These results tend to lend some support to the concept
of JAK1/2 inhibition as a potential therapeutic means in
HL. There are presently only scarce data available on the
use of ruxolitinib in HL. In a preliminary report of an
ongoing study, Kim et al. described rapid achievement of
disease control (1 complete response, 5 partial responses,
1 stable disease) in 13 patients with advanced HL treated
with ruxolitinib at a dose of 20 mg bid.29 Younes et al.
reported changes in tumor measurements in HL patients
treated in a phase I study with SB1518, an inhibitor of
JAK2 and FLT-3.30 In vitro, AZD1480, an inhibitor of JAK1
and JAK2, could regulate proliferation in HL cell lines.27
The multikinase inhibitor lestaurtinib also inhibited
growth and increased apoptosis of HL cell lines and HL
cells from lymph nodes.31 Finally, a clinical grade JAK2
inhibitor, fedratinib, inhibited the proliferation of classi-
cal HL cell lines in a JAK2 copy number-dependent man-
ner implying decreased phosphorylation of STAT and
expression of downstream targets including PD-L1 show-
ing immunomodulation by JAK inhibitors.32
If JAK2 is actually an appropriate target, questions arise
as to why the study outcome was not more convincing.
Could the drug's limited activity be attributed to insuffi-
cient dosage? Given that we observed unambiguous
cytokine profile changes and frequent improvements in B
symptoms, it would seem that the dosage of 20 mg twice
daily, a dosage at which target inhibition occurs in
myelofibrosis,33 was appropriate. Another factor possibly
influencing the outcome was our patients’ disease stage,
represented by a high percentage of refractoriness. At this
late stage, the genetic changes would be so complex that
selective inhibition of JAK is insufficient in cells depend-
ent on other signaling pathways to promote their sur-
vival, thus further curbing the study's potential. It is
known that genomic aberrations, such as chromosome
breakpoints, are more numerous in later clinical stages of
HL.34 Mechanisms of resistance to JAK/STAT inhibition
have been reported such as a feedback loop of paradoxi-
cally activated extracellular signal-regulated kinases 1 and
2 (ERK1/2).27 Aberrations of the 9p24.1 amplicon, which
contains the JAK2 gene, are more frequent in advanced
disease.28 Surprisingly, in our patients, a low incidence of
JAK2 amplification was seen, suggesting a low proportion
of patients harboring the target of ruxolitinib, although
this inference should be considered with caution since
not all patients could be analyzed. 
With respect to safety, ruxolitinib was by and large
well-tolerated, with no drug-related mortality reported.
The most prominent toxicities included drug-related ane-
mia and manageable infectious events with no specific
pattern. The relative lack of hematologic toxicity suggests
that it could be feasible to combine ruxolitinib treatment
with genotoxic compounds. For patients who discontin-
ued ruxolitinib therapy, a switch to chemotherapy and/or
immunotherapy was feasible, suggesting that the com-
pound does not jeopardize further treatment.
The question now remains as to how this compound
can best be utilized in the future. The exploratory nature
of our study did not allow identification of the best can-
didates on the basis of clinical stage or biomarkers. The
cytokine profile showed some changes in patients with
pruritus, but these changes were not correlated with clin-
ical response. Although JAK2 status was explored in a
minority of patients, the only patient with JAK2 amplifi-
cation achieved a response. It will be important to focus
on biomarker results in ongoing studies of JAK inhibition
in HL. Given ruxolitinib’s limited benefits as monothera-
py, use in combination with other drugs may possibly
enhance its therapeutic potential. Ruxolitinib, which has
no overlapping toxicity with chemotherapy, has been
combined with hypomethylating agents, lenalidomide,
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Table 4. Treatment-emergent adverse events.
A. Patients with an adverse event.
Treatment-emergent adverse events1                        All patients (n=33)
Patients with > 1 AE                                                                     14 (42.4%)
N. of  AE/patient, median (range)                                             2 (1-11)
N. of patients with AE > grade 3                                              8 (24.2%)
Patients with AE related to ruxolitinib                                     6 (18.2%)
Patients with AE leading to drug discontinuation                     1 (3%)
Patients with AE leading to death                                                 0 (0%)
AE: adverse event. 1Total number of AE, 40.
B. Characteristics of the adverse event (N = 40) by system organ class
and preferred terms
Adverse event                                   Any grade             Grade 2          Grades > 3
Any adverse event                                           40                            15                         25
Infections and infestations                          13                            10                          31
Anemia                                                               11                             0                           11
Lymphopenia                                                    4                              0                            4
Thrombocytopenia                                          2                              0                            2
Weight decrease                                              1                              0                            1
Respiratory and thoracic disorders            3                              2                            1
Diarrhea                                                             1                              1                            0
Infuenza-like illness                                        1                              1                            0
Subdural hematoma                                        1                              0                            1
Bone pain                                                           1                              1                            0
Epilepsy                                                              2                              0                            2
1Implantable device infection, gastro-enteritis, lung infection.
and even intensive chemotherapy.35-38 In vitro data have
shown that ruxolitinib could restore the sensitivity of cis-
platin-resistant cell lines with higher Jak2 expression.39
Interestingly, the combination of BV with ruxolitinib
resulted in additive and synergistic killing in a xenograft
mouse model of HL through a mechanism involving
mitochondrial control of apoptosis.40 Another means to
boost ruxolitinib’s potential would be to combine it with
agents blocking other signaling pathways. Interestingly,
the combination of ruxolitinib with a Bcl2/Bcl-xL
inhibitor displayed dramatic synergy in an adult T-cell
leukemia cell line via a mechanism implying BAX activa-
tion.41 Finally, the effect of combining chemical JAK
blockade and an anti-PD1/L1 strategy should be analyzed
in HL, keeping in mind, however, that a potential antag-
onism may be encountered due to these two drugs acting
on the same target, given that PD1-L1 expression is
dependent on JAK2 activity. 
In conclusion, based on a strong biological rationale for
clinical evaluation of JAK2 blockade in HL, we initiated a
phase II study of ruxolitinib in R/R HL patients. The
study failed to fulfill the efficacy criteria for further devel-
opment of the drug as monotherapy. Nonetheless, in
patients with very advanced disease ruxolitinib showed
hints of activity that surpassed solely an anti-inflammato-
ry effect. This may suggest that further improvements
will come from a more complete inhibition of signaling
pathways involved in HRS cell survival or from combina-
tion with chemotherapy, such as BV.
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